CDKN2A and acute lymphoblastic leukemia: On the other hand, the MRD-negative Ph-B-ALL cohort did not show any survival differences in different gene deletion groups, indicating that patients carrying CDKN2A/B deletion with a negative MRD could be potentially spared from HSCT.